BRAF and IKKα are damage-responsive kinases required for 53BP1 and RIF1 co-recruitment to sites of DNA breaks and for timely resolution of DNA lesions. This provides a novel therapeutic opportunity based on combining BRAF or IKKα inhibitors with therapeutic agents that induce DNA damage